74150-27-9 Usage
Description
Pimobendan, a novel cardiotonic vasodilator, was introduced in Japan for the
treatment of acute and mild to moderate chronic heart failure. It is a
phosphodiesterase Ⅲ inhibitor and is able to enhance sensitization of myocardial
contractile regulatory protein to calcium ions. The combination of these effects
contribute to its inotropic activity. In patients with severe congestive heart failure,
orally administered pimobendan improves cardiac index, stroke volume index,
pulmonary wedge pressure, and systemic and pulmonary vascular resistance.
Pimobendan is reported to be well tolerated and largely devoid of the proarrhythmic
effects of classical phosphodiesterase Ill inhibitors. Studies also suggested that
combination of the inotropic agent pimobendan with an ACE inhibitor such as
enalapril may be superior to monotherapy for heart failure patients.
Chemical Properties
White Solid
Originator
Boehringer
lngelhelm (Germany)
Uses
Different sources of media describe the Uses of 74150-27-9 differently. You can refer to the following data:
1. Pimobendan is a cardiotonic agent. The study of the cardiotonic mechanism of Pimobendan using ventricular muscles from rabbits and guinea pigs suggests that Pimobendan acts by inhibiting phosphodiesterase III and potassium channel. The potent venodilating action of Pimobendan makes it a suitable treatment option for patients with congestive heart failure (CHF) as it also improves systemic vasoconstriction.
2. Pimobendan is a selective inhibitor of PDE3 with IC50 of 0.32 μM. It is a drug with both inotropic and vasodilatory properties that is used for the treatment of var-ious cardiac diseases.
Definition
ChEBI: Pimobendan is a pyridazinone and a member of benzimidazoles. It has a role as a cardiotonic drug, a vasodilator agent and an EC 3.1.4.* (phosphoric diester hydrolase) inhibitor.
Brand name
Acardl
Biological Activity
Pimobendan is an inhibitor of phosphodiesterase 3 (PDE3; IC50 = 0.32 μM for guinea pig cardiac enzyme) that is selective for PDE3 over PDE1, PDE2, and PDE4 (IC50s = >30 μM). It is also a calcium sensitizer, decreasing the concentration of calcium required for half-maximal contractile force in isolated, skinned porcine ventricular fibers. Pimobendan increases the force of contraction in electrically-stimulated isolated guinea pig papillary muscles with an EC50 value of 6 μM, indicating positive inotropic effects. It increases survival time in dogs with congestive heart failure due to myxomatous mitral valve disease when administered in combination with angiotensin-converting enzyme inhibitors and furosemide . Formulations containing pimobendan have been used in the treatment of heart failure in dogs.
Biochem/physiol Actions
Pimobendan is an inotropic agent with a dual mechanism of action: it increases myocardial contractility by increasing calcium sensitization to troponin C and it promotes vasodilation by inhibiting phosphodiesterase III (PDE3). Pimobendan has been studied for treating heart failure and cardiomyopathy, primarily for veterinary uses.
Veterinary Drugs and Treatments
Pimobendan is used to treat dogs with congestive heart failure secondary
to dilated cardiomyopathy or chronic mitral valve insufficiency
(CMVI).
Check Digit Verification of cas no
The CAS Registry Mumber 74150-27-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,4,1,5 and 0 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 74150-27:
(7*7)+(6*4)+(5*1)+(4*5)+(3*0)+(2*2)+(1*7)=109
109 % 10 = 9
So 74150-27-9 is a valid CAS Registry Number.
InChI:InChI=1/C19H18N4O2/c1-11-9-16(22-23-19(11)24)13-5-8-15-17(10-13)21-18(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,23,24)/t11-/m1/s1
74150-27-9Relevant articles and documents
Preparation method of pimobendan
-
Paragraph 0015; 0022-0023, (2021/10/11)
The invention relates to a novel preparation process of pimobendan. Specifically, a Suzuki coupling reaction is carried out on a compound shown as a formula I (6-(2-bromo-1H-benzo[d]imidazol-6-yl)-5-methyl-4, 5-dihydropyridazin-3(2H)-one) and a compound shown as a formula II (p-methoxyphenylboronic acid or p-methoxyphenylboronic acid pinacol ester) under the action of a Pd catalyst, so that the preparation of the pimobendan is realized.
Novel method for preparing pimobendan from by-product for synthesizing pimobendan
-
Paragraph 0009; 0010; 0011, (2019/01/08)
The invention discloses a novel method for preparing pimobendan from a by-product for synthesizing the pimobendan. The method comprises the following steps that the by-product (the chemical name is (5RS)-6-[1-(4-methoxybenzyl)-2-(4-methoxyphenyl)-1H-benzimidazole-6-yl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone) obtained in the pimobendan synthesizing process is dissolved into a mixed solvent and reacts with ceric ammonium nitrate (CAN) at 20-25 DEG C for 2-3 hours so as to obtain a pimobendan crude product; and the obtained pimobendan crude product is heated and refluxed in an organic solvent, and cooling, filtering and drying are carried out so as to obtain the pimobendan. According to the method, the unwanted by-product is converted into a required pimobendan product, waste is turned intowealth, and therefore the production cost is greatly lowered.
PIMOBENDAN MANUFACTURING PROCESS
-
, (2011/10/31)
The present invention generally relates to an improved process for the manufacture of a non- solvated crystalline compound of formula (I). The invention further relates to a new valuable intermediate compound for the commercial synthesis of pimobendan, which is a compound according to formula (I) n MeOH, wherein n is from 1 to 2 molar equivalents. Still further, the invention relates to the use of said intermediate compound or a compound according to formula (I) obtained by the process of the invention, for the manufacture of a pharmaceutical composition.
